Wook Jang

Title: Wook Jang: Innovator in Pharmaceutical Chemistry

Introduction

Wook Jang is a prominent inventor based in Hwaseong-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific medical conditions. With a total of 2 patents to his name, Jang's work is paving the way for innovative treatments.

Latest Patents

Wook Jang's latest patents include a novel method for preparing thienopyrimidine compounds. This method selectively inhibits tyrosine kinase, specifically the mutant epidermal growth factor receptor tyrosine kinase. The invention allows for the industrial mass production of a compound that serves as a therapeutic agent for non-small cell lung cancer. His second patent involves a bicyclic derivative that effectively inhibits sodium-glucose linked transporters (SGLTs) in the intestines and kidneys. This compound can be used to treat diseases caused by hyperglycemia, including both type I and type II diabetes, as well as related complications.

Career Highlights

Wook Jang is currently employed at Hanmi Pharm. Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective therapeutic agents that address critical health issues.

Collaborations

Jang collaborates with notable colleagues such as Kwee Hyun Suh and Young Ho Moon, contributing to a dynamic research environment that fosters innovation.

Conclusion

Wook Jang's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in medicine. His patents reflect a dedication to improving health outcomes through targeted therapies.